Mechanisms of inflammatory pain: Therapeutic implications

Journal of Clinical Rheumatology

Volumn 10, Issue 3 SUPPL., 2004, Pages

  Mackey, Sean ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Analgesia; Coxibs; NSAIDs; Pain mechanisms; Prostaglandins

Indexed keywords

ANALGESIC AGENT; ANTICONVULSIVE AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DEXTROMETHORPHAN; DICLOFENAC; ETORICOXIB; GABAPENTIN; GROWTH FACTOR; KETAMINE; LAMOTRIGINE; LIDOCAINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PARECOXIB; PLACEBO; PROSTAGLANDIN; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; SODIUM CHANNEL BLOCKING AGENT; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VALDECOXIB;

ANALGESIA; ANIMAL MODEL; CHRONIC PAIN; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SPECIFICITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; LOW BACK PAIN; NEUROPATHIC PAIN; NEUROTOXICITY; NOCICEPTION; NONHUMAN; OPIATE ADDICTION; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RESPIRATION DEPRESSION; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WOUND INFECTION;

EID: 3042689729     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rhu.0000130684.35729.55     Document Type: Conference Paper

References (60)

1. Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain. 1979;6:249-252.
2. NIH Guide: New Directions in Pain Research: 1. 1998. Available at: http://grants2.nih.gov/grants/guide/pa-files/PA-98-102.html. Accessed November 10, 2003.
3. Gureje O, Von Korff M, Simon GE, et al. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA. 1998;280: 147-151.
4. Public Law 106-386, October 28, 2000. Victims of Trafficking and Violence Protection Act of 2000. Title VI, Section 1603, 'Decade of pain control and research.' Enacted October 18, 2000. Available at: http:// 209.190.246.239/ tvpa_text.pdf. Accessed November 10, 2003.
5. AdvancePCS Study Shows Top Health Conditions Cost Employers $180 Billion in Lost Productive Time [press release]. 2002. Available at: http://www.corporate-ir.net/ireye/ ir_site.zhtml?ticker=advp&script= 410&layout=&item_id=303011. Accessed November 10, 2003.
6. Besson JM. The neurobiology of pain. Lancet. 1999;353:1610-1615.
7. Scholz J, Woolf CJ. Can we conquer pain? Nat Neurosci. 2002;5(suppl): 1062-1067.
8. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965; 150:971-979.
9. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765-1769.
10. Rang HP, Bevan S, Dray A. Chemical activation of nociceptive peripheral neurones. Br Med Bull. 1991;47:534-548.
11. DuBois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J. 1998;12:1063-1073.
12. Vanegas H, Schaible HG. Prostaglandins and cyclooxygenases in the spinal cord. Prog Neurobiol. 2001;64:327-363.
13. Willingale HL, Gardiner NJ, McLymont N, et al. Prostanoids synthesized by cyclo-oxygenase isoforms in rat spinal cord and their contribution to the development of neuronal hyperexcitability. Br J Pharmacol. 1997;122:1593-1604.
14. Vasquez E, Bar KJ, Ebersberger A, et al. Spinal prostaglandins are involved in the development but not the maintenance of inflammation-induced spinal hyperexcitability. J Neurosci. 2001;21:9001-9008.
15. Beiche F, Scheuerer S, Brune K, et al. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett. 1996;390:165-169.
16. Seybold VS, Jia YP, Abrahams LG. Cyclo-oxygenase-2 contributes to central sensitization in rats with peripheral inflammation. Pain. 2003; 105:47-55.
17. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Nature. 2001;410:471-475.
18. Petersen-Felix S, Curatolo M. Neuroplasticity-an important factor in acute and chronic pain. Swiss Med Wkly. 2002;132:273-278.
19. Gracely RH, Petzke F, Wolf JM, et al. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum. 2002;46:1333-1343.
20. Scott LJ, Perry CM. Tramadol. A review of its use in perioperative pain. Drugs. 2000;60:139-176.
21. Buccellati C, Sala A, Ballerio R, et al. Tramadol anti-inflammatory activity is not related to a direct inhibitory action on prostaglandin endoperoxide synthases. Eur J Pain. 2000;4:413-415.
22. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee. Arthritis Rheum. 2000;43:1905-1915.
23. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60:1524-1534.
24. Maneuf YP, Gonzalez MI, Sutton KS, et al. Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci. 2003;60:742-750.
25. Lu Y, Westlund KR. Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. J Pharmacol Exp Ther. 1999;290:214-219.
26. Hanesch U, Pawlak M, MacDougall JJ. Gabapentin reduces the mechanosensitivity of fine afferent nerve fibres in normal and inflamed rat knee joints. Pain. 2003;104:363-366.
27. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis. 2000;31(suppl 5):S202-210.
28. Chandrasekharan NV, Dai H, Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A. 2002;99:13926-13931.
29. Kis B, Snipes JA, Isse T, et al. Putative cyclooxygenase-3 expression in rat brain cells. J Cereb Blood Flow Metab. 2003;23:1287-1292.
30. Shaftel SS, Olschowka JA, Hurley SD, et al. COX-3: a splice variant of cyclooxygenase-1 in mouse neural tissue and cells. Brain Res Mol Brain Res. 2003;119:213-215.
31. Wolfe F, Zhao S, Lane N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients. A survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum. 2000;43:378-385.
32. Pincus T, Swearingen C, Cummins P, et al. Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. J Rheumatol. 2000; 27:1020-1027.
33. Pincus T, Koch G, Lei H, et al. Patient preference for placebo, acetaminophen or celecoxib: results of 2 crossover, randomized, controlled trials in patients with osteoarthritis of the hip and knee (the PACES trials). American College of Rheumatology; Orlando, FL; October 23-28, 2003.
34. Gibofsky A, Fort JG, Mangal B, et al. Correlation between patient preference assessment and traditional measures of efficacy: results from 2 crossover, randomized, controlled trials comparing placebo, acetaminophen, and celecoxib (the PACES trials) in patients with osteoarthritis. American College of Rheumatology; Orlando, FL; October 23 28, 2003.
35. Yaksh TL, Dirig DM, Conway CM, et al. The acute antihyperanalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci. 2001;21:5847-5853.
36. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs. Arch Fam Med. 2000;9:1124-1134.
37. Pavelka K, Verburg KM. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcer: results of a 26-week trial. Rheumatology (Oxford). 2003; 42:1207-1215.
38. Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res. 2001;29:467-479.
39. Kivitz A, Eisen G, Zhao WW, et al. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract. 2002;51:530-537.
40. Makarowski W, Zhao WW, Bevirt T, et al. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002;10:290-296.
41. Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract 2002;3:10.Available at: http://www.biomed-central.com/ 1471-2296/3/10. Accessed December 5, 2003.
42. Geusens PP, Truitt K, Sfikakis P, et al. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. Scand J Rheumatol. 2002;31:230-238.
43. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA. 2002;287:64-71. Erratum in: JAMA. 2002;287:989.
44. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA. 2002;287:64-71. Erratum in: JAMA. 2002;287:989.
45. Gibofsky A, Williams GW, McKenna F, et al. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis: appropriate trial design considerations and results of a randomized, placebo-controlled trial. Arthritis Rheum. 2003;48:3102-3111.
46. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther. 1999;65:336-347.
47. Malmstrom K, Daniels S, Kotey P, et al. Comparison of rofecoxib and celecoxib, two cyclooxygenase-2 inhibitors, in postoperative dental pain: a randomized, placebo- and active-comparator-controlled clinical trial. Clin Ther. 1999;21:1653-1663.
48. Morrison BW, Christensen S, Yuan W, et al. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther. 1999;21:943-953.
49. Chang DJ, Desjardins PJ, Chen E, et al. Comparison of the analgesic efficacy of rofecoxib and enteric-coated diclofenac sodium in the treatment of postoperative dental pain: a randomized, placebo-controlled clinical trial. Clin Ther. 2002;24:490-503.
50. Fricke J, Varkalis J, Zwillich S, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther. 2002;9:89-97.
51. Khan AA, Brahim JS, Rowan JS, et al. In vivo selectivity of a selective cyclooxygenase 2 inhibitor in the oral surgery model. Clin Pharmacol Ther. 2002;72:44-49.
52. Malmstrom K, Fricke J, Kotey P, et al. A comparison of rofecoxib versus celecoxib in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. Clin Ther. 2002;10:1549-1560.
53. Norholt SE. Treatment of acute pain following removal of mandibular third molars. Use of the dental pain model in pharmacological research and development of a comparable animal model. Int J Oral Maxillofac Surg. 1998;27(suppl 1):1-41.
54. Katz N, Ju WD, Sperling RS, et al. Efficacy and safety of rofecoxib in patients with chronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group, double-blind trials. Spine. 2003;28:851-859.
55. Birbara CA, Puopolo AD, Munoz DR, et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor: improvement in pain and disability-a randomized, placebo-controlled, 3-month trial. J Pain. 2003;4:307-315.
56. Cavanaugh JM. Neural mechanisms of lumbar pain. Spine. 1995;20: 1804-1809.
57. Stephens J. A review of the burden of acute postoperative pain and the potential role of coxibs (cyclooxygenase-2-specific inhibitors). Rheumatology (Oxford). 2003;42(suppl 3):iii40-52.
58. Reuben SS, Bhopatkar S, Maciolek H, et al. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg. 2002;94:55-59.
59. Buvanendran A, Kroin JS, Tuman KJ, et al. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA. 2003;290:2411-2418.
60. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors paracoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125:1481-1492.